Neuroscience & CNS

With a cumulative team experience of over 130 years in clinical trials and the pharmaceutical industry, 4MCS (4 Medical Clinical Solutions) operates as a patient-centred Site Management Organisation dedicated to improving the quality of research in healthcare. The organisation runs its own network of research sites and recruits volunteers from a patient population of over 10 million, giving sponsors direct access to well-characterised cohorts without the delays associated with conventional site activation. The therapeutic breadth across the site's active clinical trial programme spans respiratory conditions including asthma and COPD, cardiovascular disease areas such as atrial fibrillation and hypertension, metabolic and hepatic conditions including fatty liver disease, and a range of central nervous system and dermatological indications. Migraine, depression, general anxiety disorder, myasthenia gravis, lower back pain, psoriasis, and premenopausal effects on sexual health are among the specific areas where the organisation is actively recruiting or conducting clinical research . The patient-centred model that underpins the 4MCS approach prioritises participant experience alongside data quality, with a stated mission linked to improving patient quality of life through evidence generation. The organisation maintains dedicated disease and therapy area specialisms within its leadership and operations structure, supported by an established research site infrastructure across the United Kingdom. Further information is available at 4mcs.co.uk.

AbbVie built one of the world's best-selling medicines in Humira, the anti-inflammatory biologic that reshaped the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease and held the position of the globe's top-revenue drug for over a decade. Spun out of Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie is listed on the New York Stock Exchange under the ticker ABBV and ranks among the largest pharmaceutical companies by market capitalisation. Immunology & Oncology Leadership Immunology remains the company's core franchise, anchored by Humira and its successors Skyrizi (risankizumab) and Rinvoq (upadacitinib), both of which have grown rapidly across multiple approved indications including plaque psoriasis, Crohn's disease and ulcerative colitis. In oncology , AbbVie markets Imbruvica (ibrutinib), a BTK inhibitor developed in partnership with Janssen, and Venclexta (venetoclax), a BCL-2 inhibitor co-developed with Roche, both indicated for certain blood cancers including chronic lymphocytic leukaemia. Neuroscience & Aesthetics Portfolio AbbVie significantly broadened its therapeutic reach with the 2020 acquisition of Allergan, one of the largest pharmaceutical mergers in history. That transaction brought the company Botox (both therapeutic and cosmetic), the migraine portfolio including Ubrelvy and Qulipta, and a range of medical aesthetics products. The neuroscience division now spans migraine prevention, movement disorders and psychiatry, with further pipeline candidates in Parkinson's disease and mood disorders. The aesthetics business, marketed under the Allergan Aesthetics brand, positions AbbVie as a leader in a segment beyond traditional pharmaceuticals. With operations spanning more than 70 countries and a global workforce numbering in the tens of thousands, AbbVie invests heavily in research and development, maintaining a broad pipeline across immunology, oncology, neuroscience and eye care. The company is a constituent of the S&P 500 and is widely followed for its progressive dividend policy. Further information is available at abbvie.com.

ABX-CRO operates as an independent full-service contract research organisation with a declared specialism in neuroscience, oncology and molecular imaging, applying a translational medicine approach to take compounds from early bench research through to clinical bedside application. The organisation's formal name, ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH, reflects its German origins, and its footprint has expanded internationally through both organic growth and strategic acquisitions. The service portfolio spans the full drug development continuum. On the clinical side, ABX-CRO provides radiopharmaceutical clinical trials , clinical operations, medical monitoring, pharmacovigilance, data management and biostatistics. Complementing these, the organisation offers imaging and dosimetry services alongside regulatory affairs support, preclinical and pharmacy capabilities, and project design and strategy consultancy. Medical device studies are also within scope. Several milestones mark the company's recent expansion. ABX-CRO acquired ClinSmart LLC, a Pennsylvania-based clinical quality CRO described as well-established, extending its North American presence. In India, the company secured official registration and accreditation with CDSCO as a radiopharmaceutical CRO , enabling it to conduct radiopharmaceutical clinical trials in that market. Recognition from the scientific community has also followed: ABX-CRO and Isotope Technologies Munich jointly received the Marie Curie Award from the European Association of Nuclear Medicine (EANM), acknowledging their collaborative work in the nuclear medicine field. The organisation additionally maintains an India office and a jobs programme, indicating sustained operational investment across multiple geographies. Further information is available at abx-cro.com.

Accord Healthcare ranks among the fastest-growing generic and biosimilar medicines companies in Europe, distributing products across more than 80 countries and holding one of the largest market footprints of any European generic pharmaceutical business. Established as the European commercial arm of Intas Pharmaceuticals, an Indian pharmaceutical group headquartered in Ahmedabad, Accord operates its principal EMENA base from Uxbridge, United Kingdom, with additional commercial representation in Barcelona, Spain, and a growing network of affiliates across Eastern Europe. Therapeutic Portfolio and European Reach Accord's product portfolio is built around hospital and community settings across several key therapy areas. Its oncology and haematology range forms the largest segment of the business, complemented by lines covering autoimmune conditions and central nervous system disorders. The company has delivered successive year-on-year growth in the volume of medicines launched across European markets, with its most recent annual cycle yielding the largest portfolio rollout in the company's history. A dedicated European affiliate network, with national teams across Austria, Czech Republic, Finland, France, Germany, Ireland, Italy, the Netherlands, Poland, Romania, Slovakia, Spain and Sweden, provides the commercial infrastructure to support hospital tenders and retail pharmacy channels simultaneously. Biosimilars, Animal Health and Sustainability Beyond small-molecule generics, Accord Healthcare operates at the higher-complexity end of pharmaceutical development through its biosimilars programme, where regulatory pathways and development timelines mirror those of originator biologics. This positions the company among a relatively small group of European generics firms capable of competing in both chemical and biological medicine categories. Accord also maintains an animal health division, extending the group's reach across the broader life sciences sector, alongside a patient advocacy group function that signals engagement with patient outcomes beyond the purely commercial. The company publishes environment, social and governance reporting in line with expectations from institutional partners and regulated healthcare customers across the European Union and beyond. Further information is available at accord-healthcare.com.

Addex Therapeutics is a clinical-stage pharmaceutical company advancing an emerging class of orally available small molecule drugs known as allosteric modulators , targeting neurological disorders and other indications with significant unmet need. Headquartered in Switzerland, the company combines a proprietary technology platform with a diversified pipeline spanning both clinical and pre-clinical programmes. Allosteric modulation, the mechanism at the heart of Addex's research, works by binding to sites on a receptor that are distinct from the primary active site. This approach offers potential advantages in selectivity and tolerability compared with conventional orthosteric drug design, making it a focus of growing interest in CNS drug discovery. The company's pipeline includes Dipraglurant, an mGlu5 negative allosteric modulator being evaluated for post-stroke and traumatic brain injury recovery, alongside ADX71149, an mGlu2 positive allosteric modulator developed in partnership with external collaborators. Two further GABAB positive allosteric modulator programmes address substance use disorder and chronic cough , extending the platform's reach beyond strictly neurological indications into respiratory disease. Addex supports its development activities through strategic partnerships and collaborations, which play a central role in advancing individual pipeline assets. The company is listed on the SIX Swiss Exchange and files with the SEC, maintaining US American Depositary Share (ADS) holders alongside European shareholders. Further information is available at addextherapeutics.com.

Founded in 2018 by Professor Steve Jackson in partnership with Ahren Innovation Capital, Adrestia Therapeutics was a Cambridge-based biotech that pioneered a novel approach to treating intractable genetic diseases through what it called synthetic rescue. The company's Disease Rebalancing Platform mapped gene interaction networks across the human genome to identify molecular partners capable of restoring function in damaged, diseased, or dying cells, creating a systematic atlas of therapeutic opportunities that conventional target-selection methods could not reach. Therapy Areas and Pipeline Adrestia concentrated its early programmes on neurological, neuromuscular, and cardiomyopathic diseases. A notable collaboration with Dr Sarah Tabrizi at University College London focused on Huntington's disease, while a partnership with Proteros Biostructures in Munich accelerated the identification of first-in-class small-molecule candidates across multiple targets. The company also engaged Proteros to support structural biology and drug-discovery chemistry for its lead programmes. Partnerships and Acquisition GSK co-led Adrestia's Series A financing alongside Ahren Innovation Capital, establishing a multi-project discovery collaboration in which each of up to five joint programmes was eligible for up to $230 million in post-option development and commercialisation milestones, plus royalties. In August 2023, Insmed Incorporated (Nasdaq: INSM) acquired Adrestia, integrating its synthetic rescue technology into Insmed's early-stage rare disease research portfolio. Further information is available at adrestia.com.

Mining what it describes as the deepest layers of plasma knowledge, Alkahest combines artificial intelligence, multiomics analysis and real-world data with deep plasma protein expertise to drive drug discovery. A subsidiary of Grifols, the California-based research company focuses on identifying and developing transformative therapies derived from the science of plasma. The scientific foundation underlying Alkahest's pipeline rests on the premise that the plasma proteome is in constant flux, influencing human biology in ways that can both sustain and undermine health. According to the company, alterations in plasma protein concentration and conformation are linked to multiple drivers of disease, with changes appearing years before clinical diagnosis. This positions plasma proteins as potential early biomarkers capable of informing prediction, diagnosis and treatment. A significant competitive asset is access to Grifols' plasma repository, which the company describes as one of the world's largest collections, comprising more than 100 million plasma samples gathered over nearly 15 years. The dataset spans thousands of disease states and is linked to real-world health records. Alkahest applies advanced analytical and integrative multiomics capabilities to this resource to build an evolving picture of the protein network and its relationship to human ageing and disease. The company's work sits at the intersection of plasma biology, data science and therapeutic development, representing a scientifically grounded approach to conditions where conventional small-molecule or antibody strategies have faced limitations. Further information is available at alkahest.com.

The company that proved RNA interference could be turned into medicine, Alnylam Pharmaceuticals has built the world's leading RNAi therapeutics pipeline from the ground up. Founded in Cambridge, Massachusetts in 2002, the company was established with a singular mission: to harness the natural gene-silencing mechanism of RNA interference to treat diseases at their genetic root. What was once a Nobel Prize-winning biological discovery has, under Alnylam's stewardship, become a bona fide drug class. Approved Medicines and the GalNAc Platform Alnylam's commercial portfolio spans multiple approved products targeting serious, often rare, diseases. ONPATTRO (patisiran), approved in 2018, was the first-ever RNAi therapeutic to reach patients, indicated for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). It was followed by GIVLAARI (givosiran) for acute hepatic porphyria, OXLUMO (lumasiran) for primary hyperoxaluria type 1, and LEQVIO (inclisiran, developed with Novartis) for cardiovascular cholesterol management. Central to the commercial and pipeline strategy is the proprietary GalNAc conjugate delivery platform, which enables subcutaneous dosing and has significantly broadened the range of addressable targets in the liver. Pipeline Reach and Global Presence Beyond its approved medicines, Alnylam maintains an active investigational pipeline targeting conditions including transthyretin amyloidosis with cardiomyopathy, complement-mediated diseases, and hypertension, among others. The company operates globally, with offices and partnerships spanning North America, Europe, and Asia. Alnylam trades on the Nasdaq Stock Market under the ticker ALNY and is considered a large-cap biotechnology company. Its partnerships with major pharmaceutical companies, including a long-standing collaboration with Sanofi, have reinforced its commercial infrastructure and expanded patient access internationally. Alnylam's work represents a structural shift in how genetic medicine is approached, moving from managing symptoms to silencing the genes that cause disease in the first place. For medical affairs, licensing, and pipeline enquiries, further information is available at alnylam.com.

AMO Pharma is building a portfolio of new medicines targeting serious and debilitating diseases, with a particular focus on rare and orphan genetic disorders. The privately held emerging biopharmaceutical company , headquartered in London, identifies and advances promising therapies for patient populations facing significant unmet need, guided by the principle that clinical development should deliver measurable value to patients at every stage of the journey. The pipeline reflects that commitment. AMO Pharma is progressing multiple candidates, including AMO-01, AMO-02, and AMO-04, across conditions that include Phelan-McDermid Syndrome, Rett Syndrome, and congenital myotonic dystrophy . The REACH-CDM pivotal clinical trial for congenital myotonic dystrophy represents a significant milestone in the company's development programme. Each indication falls within the rare or orphan disease space, where AMO Pharma's strategy is to identify assets with high potential impact and advance them through all phases of development, from early research through to potential approval. The company is led by a team of seasoned industry professionals who bring extensive experience in biomedical science, research, and asset acquisition across all phases of pharmaceutical development. This experienced leadership team combines deep scientific knowledge with commercial expertise, enabling a disciplined approach to candidate selection and clinical execution. AMO Pharma also maintains an active partnerships function, reflecting a business model that combines internal expertise with external collaboration to move treatments forward for underserved patient communities. Further information is available at amo-pharma.com.

Astex Pharmaceuticals applies its proprietary Pyramid Discovery Platform to the identification and development of drug candidates in oncology and central nervous system (CNS) disorders. Operating at the intersection of cutting-edge technology and translational science, the company has assembled research and development teams focused on generating innovative solutions to the complex challenges that characterise both cancer biology and CNS disease. The company has built a broad product portfolio spanning preclinical and clinical stages. Collaboration and licensing agreements with major pharmaceutical companies underpin part of that portfolio, and three partnered products have reached regulatory approval and are now available on the market. This track record of advancing candidates from discovery through to approved medicines reflects the depth of the company's drug discovery capabilities. Oncology and CNS Research Focus Astex's pipeline addresses two of the most challenging and resource-intensive areas of modern medicine. The oncology and CNS drug discovery programmes draw on proprietary technology to identify novel targets and chemical matter, with candidates progressing through preclinical characterisation into clinical evaluation. The organisation also supports early-career scientists through a postdoctoral research programme, reinforcing its commitment to sustaining innovation over the long term. Headquartered in the United Kingdom, Astex operates as a dedicated pharmaceutical research company with a clinical pipeline that continues to expand alongside its partnered development activities. Strategic partnering remains a core element of its business model, enabling the company to advance multiple assets in parallel with major industry collaborators. Further information is available at astx.com.

Biogen pioneered the neuroscience field as one of the world's oldest independent biotechnology companies, founded in 1978 by a group of distinguished scientists including Nobel laureate Walter Gilbert. Headquartered in Cambridge, Massachusetts, the company has spent nearly five decades focused almost exclusively on neurological and neurodegenerative diseases, a level of specialisation that sets it apart from diversified pharma peers. Neuroscience Focus and Key Therapy Areas Biogen's portfolio centres on multiple sclerosis , where it holds one of the broadest treatment ranges in the industry, spanning injectable, oral, and infusion therapies. The company also works in spinal muscular atrophy, Alzheimer's disease, Parkinson's disease, and rare neurological conditions. Its partnership with Eisai produced lecanemab (marketed as Leqembi), an Alzheimer's treatment that received traditional FDA approval in 2023, marking a significant moment in a field that had seen decades of clinical setbacks. Global Scale and Commercial Presence Listed on the Nasdaq under the ticker BIIB, Biogen operates across more than 30 countries, with commercial infrastructure spanning North America, Europe, and Asia Pacific. The company invests heavily in research and development as a proportion of revenue, consistent with its identity as a science-led organisation rather than a marketing-driven one. Its biosimilars division, built through a long-standing collaboration with Samsung Bioepis, gives Biogen a commercial presence in the cost-sensitive biologics market alongside its branded neurology pipeline. Biogen has also expanded into rare disease and neuropsychiatry, reflecting a strategic effort to broaden the neuroscience platform beyond multiple sclerosis as the MS market faces increasing genericisation. The company's gene therapy interests, including assets in-licensed and acquired over recent years, signal further ambition in treating diseases at the molecular level. For professionals in pharmaceutical, biotech, and medical research sectors, Biogen represents one of the most focused large-cap neuroscience organisations operating globally. Further information is available at biogen.com.

Eli Lilly and Company is one of the oldest continuously operating pharmaceutical companies in the United States, founded in Indianapolis in 1876 by Colonel Eli Lilly, a Civil War veteran who insisted on rigorous quality standards at a time when patent medicines were largely unregulated. That founding conviction shaped a company that today ranks among the world's largest pharmaceutical enterprises by market capitalisation, listed on the New York Stock Exchange under the ticker LLY. Diabetes & Metabolic Disease Leadership Lilly's most consequential scientific legacy is in diabetes care . The company played a central role in the commercialisation of insulin in the early 1920s and has remained a dominant force in the category ever since. Its portfolio of insulin products and GLP-1 receptor agonist treatments has placed it at the forefront of the global obesity and metabolic disease conversation, with Mounjaro (tirzepatide) representing one of the highest-profile pharmaceutical launches of the 2020s across both type 2 diabetes and weight management indications. Oncology & Neuroscience Portfolio Beyond metabolic disease, Lilly operates a substantial oncology division spanning targeted therapies and immuno-oncology, alongside a long-standing neuroscience programme that has historically focused on depression, pain, and central nervous system disorders. The company has invested heavily in Alzheimer's disease research, an area where it has pursued multiple clinical programmes over several decades. Verzenio (abemaciclib) in breast cancer and Cyramza (ramucirumab) in gastric and lung malignancies anchor the oncology commercial offering. Headquartered in Indianapolis, Indiana, Lilly operates manufacturing sites, research laboratories, and commercial offices across dozens of countries, serving patients in more than 120 markets globally. The company's R&D investment consistently ranks among the highest in the industry as a proportion of revenue, reflecting a pipeline-first culture that has defined its competitive positioning for generations. Further information is available at lilly.com.